Pulmonary Epithelial Dynamics and Innate Host Defense
Pulmonary Epithelial Dynamics and Innate Host Defense
批准号:
10063952
负责人:
Francis Xavier McCormack
金额:
$48.1万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-12-07 至 2022-11-30
关键词:
Adrenal Cortex HormonesAffectAir SacsAlveolarAlveolitisAlveolusApoptosisApoptoticBRAF geneBindingBronchiolitisBronchitisCell CycleCell ProliferationCell modelCell surfaceCellsCenters for Disease Control and Prevention (U.S.)Cessation of lifeChronicClinicalCough HeadachesCoughingCytoplasmDataDevelopmentDoseElderlyEndocytosisEpidemicEpithelialEpithelial CellsEventFRAP1 geneFeverFibroblast Growth Factor ReceptorsGenesGenetic ModelsGoalsHost DefenseHumanHyperoxiaImmuneIn VitroIncidenceInfectionInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza A virusInhalationIntegration Host FactorsLigand BindingLungMAP Kinase GeneMAPK Signaling Pathway PathwayMEKsMembrane GlycoproteinsMitogensModelingMouse Cell LineMusMyalgiaNatural ResistancePI3K/AKTPathway interactionsPlayPneumoniaPre-Clinical ModelPredispositionProcessProductionProphylactic treatmentProteinsPulmonary Heart DiseaseRNA VirusesRandomized Controlled TrialsReceptor Protein-Tyrosine KinasesRecoveryResistanceResistance to infectionRoleSeveritiesSialic AcidsSignal TransductionSirolimusStimulusSyndromeTamoxifenTestingTherapeuticTracheitisTubeViralVirusVirus DiseasesVirus Replicationalveolar epitheliumalveolar type II cellin vivoinfluenza infectioninfluenza pneumoniainfluenzavirusinhibitor/antagonistkeratinocyte growth factorlung injurymTOR Inhibitormortalitynovelnovel strategiesprenatal cigarette smokingresistance mechanismsialic acid receptor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
The RNA virus that causes influenza is inhaled into the airways and binds to terminal sialic acid residues on
host cell surface glycoproteins via viral sialic acid receptors. The tracheitis, bronchitis and bronchiolitis that
results is often accompanied by incapacitating cough, headache, fever and myalgias, but the syndrome usually
resolves in 7-10 days without development of alveolitis. This is fortunate because once the pulmonary
parenchyma is involved, mortality increases almost 60 fold, from 0.3 to 17.8 annual deaths per 100,000(2006
CDC data). Because we believe that infection of alveolar type II (ATII) cells is the pivotal event in the
conversion of a self-limited influenza virus (IV) airway infection to a potentially lethal alveolar infection, our
proposal focuses on the mechanisms that render the ATII cells resistant or susceptible to infection with IV.
Although ATII cells are clearly the primary epithelial target for IV in the alveolus, they are remarkably resistant
to IV infection in their typically quiescent state in the unperturbed lung, in which fewer than 1% of ATII cells are
cycling. Recent in vitro studies have demonstrated that the PI3K/Akt/mTOR pathway, which regulates cellular
proliferation, plays a key role in susceptibility and severity of IV infection by enhancing cell surface binding,
endocytosis, lysosomal acidification driven entry into the cytoplasm, replication using cellular translational
machinery, and anti-apoptotic mechanisms that prolong viral production. Mitogenic stimulation of
PI3K/Akt/mTOR pathway with intrapulmonary keratinocyte growth factor (KGF) converts ATII cells from a
quiescent, IV resistant state to a proliferative, IV susceptible state, and hastens the progression of IV infection
from the conducting airways to the alveolus, markedly accelerating mortality. Our hypothesis is that key host
factors, such as transient hyperoxia, render hosts susceptible to influenza pneumonia (IP) through their impact
on the proliferative tone of the ATII pool. Our goals are to determine the mechanisms of mitogen-induced
susceptibility to influenza A virus susceptibility by completing three specific aims: 1) mechanisms of mitogen-
induced susceptibility of AECII cells to IAV infection, 2) host states that affect IAV susceptibility through
mitogenic effects on AECII cells, 3) genetic models of AECII signaling and anti-proliferative strategies for IAV
prophylaxis and therapy. Successful completion of these aims will reveal the importance of a paradigm-shifting,
AECII-centric host susceptibility mechanism, and suggest novel approaches to influenza prophylaxis and
therapy.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.3389/fmicb.2021.774711
发表时间:
2021
期刊:
Frontiers in microbiology
影响因子:
5.2
作者:
[White MR, Nikolaidis NM, McCormack F, Crouch EC, Hartshorn KL]
通讯作者:
Hartshorn KL
Novel Mechanisms of Pulmonary Fibrosis
-
批准号:10660225
-
项目类别:
-
资助金额:$64.31万
-
财政年份:2023
-
负责人:Francis Xavier McCormack
-
依托单位:
Role of Pulmonary Osteoclast-Like Cells in Lung Injury
-
批准号:10395922
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Francis Xavier McCormack
-
依托单位:
Role of Pulmonary Osteoclast-Like Cells in Lung Injury
-
批准号:10115416
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Francis Xavier McCormack
-
依托单位:
Role of Pulmonary Osteoclast-Like Cells in Lung Injury
-
批准号:10620655
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Francis Xavier McCormack
-
依托单位:
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED)-CCC
-
批准号:10219338
-
项目类别:
-
资助金额:$53.66万
-
财政年份:2016
-
负责人:Francis Xavier McCormack
-
依托单位:
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED)-CCC
-
批准号:9742512
-
项目类别:
-
资助金额:$64.95万
-
财政年份:2016
-
负责人:Francis Xavier McCormack
-
依托单位:
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED)-CCC
-
批准号:9355218
-
项目类别:
-
资助金额:$79.83万
-
财政年份:2016
-
负责人:Francis Xavier McCormack
-
依托单位:
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED)-CCC
-
批准号:9520409
-
项目类别:
-
资助金额:$87.03万
-
财政年份:2016
-
负责人:Francis Xavier McCormack
-
依托单位:
Pathogenesis-Driven Therapeutic Development for Pulmonary Alveolar Microlithiasis
-
批准号:9247827
-
项目类别:
-
资助金额:$39.45万
-
财政年份:2015
-
负责人:Francis Xavier McCormack
-
依托单位:
Pathogenesis-Driven Therapeutic Development for Pulmonary Alveolar Microlithiasis
-
批准号:9032527
-
项目类别:
-
资助金额:$39.47万
-
财政年份:2015
-
负责人:Francis Xavier McCormack
-
依托单位:
Pathogenesis-Driven Therapeutic Development for Pulmonary Alveolar Microlithiasis
-
批准号:8864887
-
项目类别:
-
资助金额:$40.94万
-
财政年份:2015
-
负责人:Francis Xavier McCormack
-
依托单位:
FASEB SRC: The Lung Epithelium in Health & Disease
-
批准号:8398679
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2012
-
负责人:Francis Xavier McCormack
-
依托单位:
2015 LAM Foundation International Lymphangioleiomyomatosis Conference
-
批准号:8911573
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2008
-
负责人:Francis Xavier McCormack
-
依托单位:
2012 International LAM Research Conference
-
批准号:8318344
-
项目类别:
-
资助金额:$1.9万
-
财政年份:2008
-
负责人:Francis Xavier McCormack
-
依托单位:
2010 NHLBI/LAM Foundation International Lymphangioleiomyomatosis Research Confere
-
批准号:7914939
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2008
-
负责人:Francis Xavier McCormack
-
依托单位:
2016 LAM Foundation International Lymphangioleiomyomatosis Research Conference
-
批准号:9195335
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2008
-
负责人:Francis Xavier McCormack
-
依托单位:
2013 LAM Symposium
-
批准号:8529127
-
项目类别:
-
资助金额:$1.8万
-
财政年份:2008
-
负责人:Francis Xavier McCormack
-
依托单位:
2008 LAM Foundation International Research Conference
-
批准号:7533086
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2008
-
负责人:Francis Xavier McCormack
-
依托单位:
2011 International LAM Research Conference
-
批准号:8130041
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2008
-
负责人:Francis Xavier McCormack
-
依托单位:
PHASE III TRIAL FO SIROLIMUS IN LYMPHANGIOLEIOMYLMATOSIS
-
批准号:7679040
-
项目类别:
-
资助金额:$34.86万
-
财政年份:2007
-
负责人:Francis Xavier McCormack
-
依托单位:
海外基金